Clinical trial
Use of Sugammadex at the End of Case in Routine Anesthesia (MK-8616-023)
NCT00298831 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00298831 |
|---|---|
| Title | Use of Sugammadex at the End of Case in Routine Anesthesia (MK-8616-023) |
| Official title | A Multicenter, Open Label, Phase IIIa Trial to Evaluate the Efficacy and Safety of Org 25969 When Used at the End of a Surgical Procedure to Reverse the Neuromuscular Block Induced by Rocuronium Following Routine Anesthesia |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Anesthesia, General |
| Intervention type | Drug |
| Interventions | Sugammadex, Rocuronium |
| Enrollment | 224 |
| Start date | Oct 27, 2005 |
| Primary completion | May 22, 2006 |
| Completion | May 22, 2006 |
| First posted | Mar 3, 2006 |
| Last update posted | Mar 27, 2019 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: